Cargando…

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives

Antineutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by inflammation of the vascular wall. The pathogenesis of AAV is strongly associated with B cell-derived ANCAs; thus, Rituximab (RTX) has become a promising drug in the induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Treppo, Elena, Binutti, Marco, Agarinis, Roberto, De Vita, Salvatore, Quartuccio, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432126/ https://www.ncbi.nlm.nih.gov/pubmed/34501224 http://dx.doi.org/10.3390/jcm10173773

Ejemplares similares

Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases
por: Quartuccio, Luca, et al.
Publicado: (2020)

Unmet needs in ANCA-associated vasculitis: Physicians’ and patients’ perspectives
por: Quartuccio, Luca, et al.
Publicado: (2023)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
por: Austin, Keziah, et al.
Publicado: (2022)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives
por: Samman, Karla N., et al.
Publicado: (2021)

Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art
por: Bonatti, Francesco, et al.
Publicado: (2014)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Boon and bane of remission induction with rituximab in ANCA-associated vasculitis: lessons learned from the RAVE-ITN follow-up study
por: Kronbichler, Andreas
Publicado: (2013)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

ANCA Vasculitis Induction Management During the COVID-19 Pandemic
por: Salas, Antonio, et al.
Publicado: (2021)

Normal-Appearing Salivary Gland Ultrasonography Identifies a Milder Phenotype of Primary Sjögren's Syndrome
por: Zandonella Callegher, Sara, et al.
Publicado: (2020)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial
por: Maritati, Federica, et al.
Publicado: (2017)

Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression
por: Agrawal, Amogh, et al.
Publicado: (2023)

Management of ANCA-associated vasculitis: Current trends and future prospects
por: Hamour, Sally, et al.
Publicado: (2010)

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study
por: Ysermans, Renée, et al.
Publicado: (2022)

The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study
por: Roccatello, Dario, et al.
Publicado: (2017)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

ANCA‐associated vasculitis with scleritis, corneal melt, and perforation rescued by rituximab: Case report and literature review
por: Matsuo, Toshihiko, et al.
Publicado: (2023)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Thietart, Sara, et al.
Publicado: (2022)

Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation
por: Quartuccio, Luca, et al.
Publicado: (2009)

Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis
por: Floyd, Lauren, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jpntqcg0qh664dm78rq4ui0rb5